CYCLOSERINE AND CYPROHEPTADINE TREATMENT OF DEPERSONALIZATION

环丝氨酸和赛庚啶治疗人格解体

• 批准号: 7380530
• 负责人: DAPHNE SIMEON
• 金额: $ 0.16万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-17 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7380530
• 关键词: anticonvulsants; arm; comorbidity; conditioning; emotions; glycine; person with disability

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Depersonalization disorder (DPD) is a chronic, disabling psychiatric condition that is characterized by feelings of estrangement, detachment, and disconnection from one's sense of self. Currently, there are no approved pharmacological agents for the treatment of DPD. Recent controlled trials of both SSRI and lamotrigine in DPD unfortunately proved negative. State-of-the-art psychopharmacologic treatment for the disorder is currently conducted without proven efficacy or systematic guidelines for any medication. Pharmacologists usually attempt to use a variety of marketed medications on the basis of the symptom and comorbidity profile of each individual patient. However, based both on theoretical reasoning and case report data, there is reason to hypothesize that the NMDA partial glycine agonist D-cycloserine (DCS) and the 5HT2A and C antagonist cyproheptadine (CH) may have some efficacy in the treatment of DPD. We therefore propose to conduct a pilot crossover medication treatment study consisting of an 8-week open treatment arm with DCS and an 8-week open treatment arm with CH, administered in randomized sequence with a 2-week washout period in 15 subjects currently suffering from DSM-IV depersonalization.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。人格解体障碍（DPD）是一种慢性、致残的精神疾病，其特征是疏远、疏离和与自我感脱节的感觉。目前，没有批准用于治疗DPD的药理学药剂。最近SSRI和拉莫三嗪在DPD中的对照试验不幸地被证明是阴性的。目前对这种疾病的最先进的精神药理学治疗是在没有任何药物的有效性或系统指南的情况下进行的。药理学家通常尝试根据每个患者的症状和合并症特征使用各种市售药物。然而，根据理论推理和病例报告数据，有理由假设NMDA部分甘氨酸激动剂D-环丝氨酸（DCS）和5 HT 2A和C拮抗剂赛庚啶（CH）可能对治疗DPD有一定疗效。因此，我们建议在15例目前患有DSM-IV人格解体的受试者中进行一项试点交叉药物治疗研究，包括一个为期8周的开放治疗组（DCS）和一个为期8周的开放治疗组（CH），以随机序列给药，洗脱期为2周。